Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA4 | P22748 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25180667 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL8957343 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1842696 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL25180691 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL8957403 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL25184217 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| Ammonia Solution, Strong SCHEMBL9446994 | 0.97 | CA12 (0.48) | CA12CA1CA2CA4CA9 | |
| Ammonia Solution, Strong SCHEMBL6736966 | 0.97 | CA12 (0.48) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1220763 | 0.97 | CA12 (0.48) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4731008 | 0.90 | CA12 (0.48) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115832436-A | Lithium secondary battery electrolyte with high and low temperature performance and lithium secondary battery | 广州天赐高新材料股份有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-113054258-A | Novel application of substituted silicon-based phosphate compound, electrolyte and lithium ion battery | 广州天赐高新材料股份有限公司 | 2021-06-29 | — | — | CN | claimed |
| EP-1079823-A1 | COMPOSITIONS COMPRISING ORGANIC MONO- OR DINITRATE FOR TREATING IMPOTENCE | BAKER NORTON PHARMACEUTICALS, INC. (US) | 2001-03-07 | — | — | EP | claimed |
| US-6056966-A | ORGANIC MONO- OR DINITRATE IN A PHARMACEUTICALLY ACCEPTABLE TOPICAL OR PARENTERAL CARRIER | BAKER NORTON PHARMACEUTICALS, INC. (US) | 2000-05-02 | — | — | US | claimed |
| WO-1999059575-A1 | COMPOSITIONS COMPRISING ORGANIC MONO- OR DINITRATE FOR TREATING IMPOTENCE | BAKER NORTON PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | claimed |
| US-5049694-A | Cardiovascular disorders | CEDONA PHARMACEUTICALS B.V. (NL) | 1991-09-17 | — | — | US | claimed |
| US-12612356-B2 | Process for nitrate ester formation of an α,ω-alkanediol monoacylate | DSM IP ASSETS B.V. (NL) | 2026-04-28 | — | — | US | disclosed |
| US-12522558-B2 | Process for the acylation of an alpha, omega-alkanediol | DSM IP ASSETS B.V. (CH) | 2026-01-13 | — | — | US | disclosed |
| WO-2024121144-A1 | METHOD FOR PROVIDING APPLICATION DATA FOR APPLYING A METHANE INHIBITOR PRODUCT ON AN AGRICULTURAL FLOODED FIELD | BASF SE (DE) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121139-A1 | REDUCING METHANE EMISSIONS OF A FLOODED FIELD | BASF SE (DE) | 2024-06-13 | — | — | WO | disclosed |
| EP-4139279-B1 | PROCESS FOR THE ACYLATION OF AN ALPHA,OMEGA-ALKANEDIOL | DSM IP ASSETS BV (NL) | 2024-04-17 | — | — | EP | disclosed |
| US-20240084208-A1 | NEW MIXTURES FOR IMPROVING THE STABILITY OF ADDITIVE PACKAGES | BASF SE (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20240034941-A1 | NEW MIXTURES FOR IMPROVING OR BOOSTING THE SEPARATION OF WATER FROM FUELS | BASF SE (DE) | 2024-02-01 | — | — | US | disclosed |
| EP-0467628-B1 | Fuel compositions with enhanced combustion characteristics | ETHYL PETROLEUM ADDITIVES INC (US) | 1993-12-22 | — | — | EP | disclosed |
| EP-0537931-A1 | Fuel compositions | ETHYL PETROLEUM ADDITIVES, INC. (US) | 1993-04-21 | — | — | EP | disclosed |
| EP-0467628-A1 | Fuel compositions with enhanced combustion characteristics | ETHYL PETROLEUM ADDITIVES, INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| EP-0457589-A1 | Fuel compositions with enhanced combustion characteristics | ETHYL PETROLEUM ADDITIVES, INC. (US) | 1991-11-21 | — | — | EP | disclosed |
| US-5049694-A | Cardiovascular disorders | CEDONA PHARMACEUTICALS B.V. (NL) | 1991-09-17 | — | — | US | disclosed |
| EP-0359335-A2 | Pharmaceutical composition having relaxing activity which contains a nitrate ester as active substance | CEDONA PHARMACEUTICALS B.V. (NL) | 1990-03-21 | — | — | EP | disclosed |
| US-3943820-A | Method for charging drill holes with explosive | NITRO NOBEL AB (SW) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612356-B2 | Process for nitrate ester formation of an α,ω-alkanediol monoacylate | ELOVL3, ELOVL1, PTGES | CA12 1956/4885CA1 2237/4885CA2 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.